[New molecular therapy options in hematology and oncology, exemplified by STI571].
Schleuning
M
M
Medizinische Klinik III, Klinikum Grosshadern der Ludwig-Maximilians-Universität München.
Hiddemann
W
W
D001549:Benzamides; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005858:Germany; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000494:pharmacology* / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use; D012074:Remission Induction
D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases